Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery

Pharmaceuticals (Basel). 2022 Aug 8;15(8):975. doi: 10.3390/ph15080975.

Abstract

The oral route is the most common and practical means of drug administration, particularly from a patient's perspective. However, the pharmacokinetic profile of oral drugs depends on the rate of drug absorption through the intestinal wall before entering the systemic circulation. However, the enteric epithelium represents one of the major limiting steps for drug absorption, due to the presence of efflux transporters on the intestinal membrane, mucous layer, enzymatic degradation, and the existence of tight junctions along the intestinal linings. These challenges are more noticeable for hydrophilic drugs, high molecular weight drugs, and drugs that are substrates of the efflux transporters. Another challenge faced by oral drug delivery is the presence of first-pass hepatic metabolism that can result in reduced drug bioavailability. Over the years, a wide range of compounds have been investigated for their permeation-enhancing effect in order to circumvent these challenges. There is also a growing interest in developing nanocarrier-based formulation strategies to enhance the drug absorption. Therefore, this review aims to provide an overview of the challenges faced by oral drug delivery and selected strategies to enhance the oral drug absorption, including the application of absorption enhancers and nanocarrier-based formulations based on in vitro, in vivo, and in situ studies.

Keywords: absorption enhancers; intestinal absorption; nanocarriers; oral delivery; pharmacokinetic profile.

Publication types

  • Review

Grants and funding

The authors gratefully acknowledge the research grant from Universiti Teknologi MARA in the form of ((DUCS) 2.0; 600-UiTMSEL (PI. 5/4) (016/2020)), 600-UITMSEL (PI. 5/4) (037/2022) and 600-RMC/GIP 5/3 (075/2022).